Dr. med. Martina Crysandt

Dr. med. Martina Crysandt
Tel.: 0241 80-80655



Allogene Stammzelltransplantation

Akute myeloische Leukämie (AML)




Wissenschaftliche Schwerpunkte

Epigenetik (CML)

Molekulargenetik nach allogener Stammzelltransplantation


Ausgewählte Publikationen

Crysandt M, Hilgers RD, von Hobe S, Eisert A, Jost E, Panse J, Brummendorf TH, Wilop S (2011) Hypercholesterolemia and its association with enhanced stem cell mobilization and harvest after high-dose cyclophosphamide+G-CSF. Bone Marrow Transplant 46(11):1426-9

Crysandt M, Lemmen SW, Jost E, Brummendorf TH, Osieka R, Wilop S (2010) Antineoplastic chemotherapy in cancer patients with methicillin-resistant Staphylococcus aureus (MRSA). Onkologie 33(11):598-603

Wilop S, von Hobe S, Crysandt M, Esser A, Osieka R, Jost E (2009) Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy. J Cancer Res Clin Oncol 135(10):1429-35

Wilop S, Crysandt M, Bendel M, Mahnken AH, Osieka R, Jost E (2008) Correlation of C-reactive protein with survival and radiographic response to first-line platinum-based chemotherapy in advanced non-small cell lung cancer. Onkologie 31(12):665-70

Crysandt M, Neumann B, Das M, Engelbertz V, Bendel M, Galm O, Osieka R, Jost E (2007) Intraperitoneal application of rituximab in refractory mantle cell lymphoma with massive ascites resulting in local and systemic response. Eur J Haematol 79(6):546-9